Quantcast
Last updated on April 16, 2014 at 11:22 EDT

Latest Sitaxentan Stories

2013-09-16 12:28:12

LAVAL, QC, Sept. 16, 2013 /CNW/ - Actelion Pharmaceuticals Canada Inc. announced today that CARIPUL®( )(epoprostenol) for Injection is now available in Canada. CARIPUL® is a prescription medication indicated for the long-term intravenous treatment of primary pulmonary hypertension (or idiopathic pulmonary arterial hypertension), and secondary pulmonary hypertension due to scleroderma spectrum of diseases in NYHA functional Class III and Class IV patients who did not respond...

Common Lung Blood Pressure Drug May Damage The Heart
2013-01-22 09:02:22

April Flowers for redOrbit.com - Your Universe Online A new study led by the Faculty of Medicine & Dentistry at the University of Alberta significantly improves understanding of how widely used drugs in pulmonary arterial hypertension (PAH) affect the heart health of patients who use them. The findings of this study, published in a recent issue of Circulation Research, a journal of the American Heart Association, reveal that the medications most often prescribed for PAH could block...

2012-10-23 15:25:17

WAYNE, N.J., Oct. 23, 2012 /PRNewswire/ -- Bayer HealthCare today announced data from the Phase III CHEST-1 trial evaluating its investigational drug riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent pulmonary hypertension (PH) after surgery. The results showed the CHEST-1 study met its primary endpoint by demonstrating a statistically significant improvement in the six-minute walk distance (6MWD). In the study,...

2012-10-21 23:21:08

WAYNE, N.J., Oct. 22, 2012 /PRNewswire/ -- Bayer HealthCare today announced data from the Phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug riociguat in both treatment-naive patients and those pre-treated with an endothelin receptor antagonist or an oral, inhaled or subcutaneous prostanoid. The study met its primary endpoint by demonstrating a statistically significant improvement in the six-minute walk distance (6MWD) with patients treated...

2011-09-25 06:03:00

EAST HANOVER, N.J., Sept. 25, 2011 /PRNewswire/ -- Novartis announced new data today from the pivotal Phase III IMPRES clinical trial showing that the investigational therapy QTI571 (imatinib) significantly improved exercise capacity in patients with pulmonary arterial hypertension (PAH) after 24 weeks compared with placebo(1). Evidence indicates that QTI571 targets an underlying cause of PAH by counteracting uncontrolled growth of arterial smooth muscle cells(2). The IMPRES study met...

2011-05-04 10:00:00

SAN DIEGO, May 4, 2011 /PRNewswire/ -- Aires Pharmaceuticals, Inc. today announced the hiring of Ed Parsley, D.O. as Chief Medical Officer. Dr. Parsley will fill a key role on Aires' leadership team and will be responsible for all clinical development activities for Aironite(TM), the company's lead product for treatment of pulmonary arterial hypertension (PAH). Dr. Parsley joins Aires from Pfizer where he was the Clinical Lead for ongoing clinical trials for Revatio (Sildenafil), Pfizer's...

2011-05-04 09:45:00

WESTMINSTER, Colo., May 4, 2011 /PRNewswire/ -- Plato BioPharma, Inc. (PBI) and Gilead Sciences, Inc. will be jointly presenting a thematic poster at the "Novel Therapeutics in Pulmonary Fibrosis" session at the 2011 American Thoracic Society (ATS) International Conference in Denver, Colorado on May 18, 2011. The poster entitled Differing Effects of Ambrisentan and Bosentan on Pulmonary Fibrosis and Lung Mechanics Following Bleomycin Instillation will be presented by John Liles, PhD of...

2011-04-09 04:09:18

A new study has demonstrated no significant benefit of taking the drug bosentan for idiopathic pulmonary fibrosis (IPF). The results were published online ahead of the print edition in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. Read the full study here. Although the primary endpoint of the Bosentan Use in Interstitial Lung Disease (BUILD)-3 study was not attained, researchers point to the possibility of benefit for a subset of IPF patients who...

2011-03-04 14:18:00

Monthly liver enzyme testing is no longer required SILVER SPRING, Md., March 4, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that monthly liver enzyme tests are no longer required for those taking Letairis tablets (ambrisentan), used to treat high blood pressure in the vessels that carry blood to the lungs (pulmonary arterial hypertension, or PAH). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Citing data from clinical trials and...

2010-12-10 07:00:00

NEW YORK, Dec. 10, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that, in the interest of patient safety, it is voluntarily withdrawing Thelin® (sitaxentan) for the treatment of pulmonary arterial hypertension (PAH) in regions where it is approved (the European Union, Canada and Australia). In addition, Pfizer is discontinuing clinical studies of Thelin worldwide. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ) Pfizer's decision...